Top

The European Journal of Health Economics

Published in:

Open Access 01-07-2016 | Original Paper

Health resource utilization associated with skeletal-related events: results from a retrospective European study

Authors: Jean-Jacques Body, João Pereira, Harm Sleeboom, Nikos Maniadakis, Evangelos Terpos, Yves Pascal Acklin, Jindrich Finek, Oliver Gunther, Guy Hechmati, Tony Mossman, Luis Costa, Wojciech Rogowski, Hareth Nahi, Roger von Moos

Published in: The European Journal of Health Economics | Issue 6/2016

Abstract

Background

Bone complications, also known as skeletal-related events (SREs), are common in patients with bone metastases secondary to advanced cancers.

Objective

To provide a detailed estimate of the health resource utilization (HRU) burden associated with SREs across eight European countries.

Methods

Eligible patients from centers in Austria, the Czech Republic, Finland, Greece, Poland, Portugal, Sweden, and Switzerland with bone metastases or lesions secondary to breast cancer, prostate, or lung cancer or multiple myeloma who had experienced at least one SRE (defined as radiation to bone, long-bone pathologic fracture, other bone pathologic fracture, surgery to bone or spinal cord compression) were entered into this study. HRU data were extracted retrospectively from the patients’ charts from 3.5 months before the index SRE until 3 months after the index SRE (defined as an SRE preceded by an SRE-free period of at least 6.5 months).

Results

Overall, the mean number of inpatient stays per SRE increased from baseline by approximately 0.5–1.5 stays, with increases in the total duration of inpatient stays of approximately 6–37 days per event. All SREs were associated with substantial increases from baseline in the frequency of procedures and the number of outpatient and day-care visits.

Conclusions

SREs are associated with substantial HRU owing to considerable increases in the number and duration of inpatient stays, and in the number of procedures, outpatient visits, and day-care visits. These data collectively provide a valuable summary of the real-world SRE burden on European healthcare systems.

Parker, C., Nilsson, S., Heinrich, D., Helle, S.I., O’Sullivan, J.M., Fossa, S.D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D.C., Hoskin, P., Bottomley, D., James, N.D., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., Boehmer, S., Dall’Oglio, M., Franzen, L., Coleman, R., Vogelzang, N.J., O’Bryan-Tear, C.G., Staudacher, K., Garcia-Vargas, J., Shan, M., Bruland, O.S., Sartor, O., Investigators, A.: Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369(3), 213–223 (2013). doi:10.1056/NEJMoa1213755 CrossRefPubMed

Coleman, R.E.: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12(20 Pt 2), 6243s–6249s (2006). doi:10.1158/1078-0432.CCR-06-0931 CrossRefPubMed

Coleman, R.E.: Skeletal complications of malignancy. Cancer 80(8 Suppl), 1588–1594 (1997). doi:10.1002/(SICI)1097-0142(19971015)80 CrossRefPubMed

Costa, L., Badia, X., Chow, E., Lipton, A., Wardley, A.: Impact of skeletal complications on patients’ quality of life, mobility, and functional independence. Support. Care Cancer 16(8), 879–889 (2008). doi:10.1007/s00520-008-0418-0 CrossRefPubMed

Norgaard, M., Jensen, A.O., Jacobsen, J.B., Cetin, K., Fryzek, J.P., Sorensen, H.T.: Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J. Urol. 184(1), 162–167 (2010). doi:10.1016/j.juro.2010.03.034 CrossRefPubMed

Saad, F., Lipton, A., Cook, R., Chen, Y.M., Smith, M., Coleman, R.: Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110(8), 1860–1867 (2007). doi:10.1002/cncr.22991 CrossRefPubMed

Sathiakumar, N., Delzell, E., Morrisey, M.A., Falkson, C., Yong, M., Chia, V., Blackburn, J., Arora, T., Brill, I., Kilgore, M.L.: Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006. Breast Cancer Res. Treat. 131(1), 231–238 (2012). doi:10.1007/s10549-011-1721-x CrossRefPubMed

Felix, J., Andreozzi, V., Soares, M., Borrego, P., Gervasio, H., Moreira, A., Costa, L., Marcelo, F., Peralta, F., Furtado, I., Pina, F., Albuquerque, C., Santos, A., Passos-Coelho, J.L.: Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System. Value Health. 14(4), 499–505 (2011). doi:10.1016/j.jval.2010.11.014 CrossRefPubMed

Mahmood, A., Ghazal, H., Fink, M.G., Patel, M., Atchison, C., Wei, R., Suenaert, P., Pinzone, J.J., Slasor, P., Chung, K.: Health-resource utilization attributable to skeletal-related events in patients with advanced cancers associated with bone metastases: results of the US cohort from a multicenter observational study. Comm. Oncol. 9, 148–157 (2012)CrossRef

10.

Pockett, R.D., Castellano, D., McEwan, P., Oglesby, A., Barber, B.L., Chung, K.: The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur. J. Cancer Care (Engl.) 19(6), 755–760 (2010). doi:10.1111/j.1365-2354.2009.01135.x CrossRef

11.

Groot, M.T., Boeken Kruger, C.G., Pelger, R.C., Uyl-de Groot, C.A.: Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur. Urol. 43(3), 226–232 (2003). doi:10.1016/S0302-2838(03)00007-1 CrossRefPubMed

12.

Botteman, M., Barghout, V., Stephens, J., Hay, J., Brandman, J., Aapro, M.: Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann. Oncol. 17(7), 1072–1082 (2006). doi:10.1093/annonc/mdl093 CrossRefPubMed

13.

Delea, T., McKiernan, J., Brandman, J., Edelsberg, J., Sung, J., Raut, M., Oster, G.: Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J. Support. Oncol. 4(7), 341–347 (2006)PubMed

14.

Hechmati, G., Cure, S., Gouepo, A., Hoefeler, H., Lorusso, V., Luftner, D., Duran, I., Garzon-Rodriguez, C., Ashcroft, J., Wei, R., Ghelani, P., Bahl, A.: Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. J. Med. Econ. 16(5), 69–700 (2013). doi:10.3111/13696998.2013.779921 CrossRef

15.

Hoefeler, H., Duran, I., Hechmati, G., Garzon Rodriguez, C., Lüftner, D., Ashcroft, J., Bahl, A., Atchison, C., Wei, R., Thomas, E., Lorusso, V.: Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective––prospective observational study––a cohort from 4 European countries. J. Bone Oncol. 3(2), 40–48 (2014)CrossRefPubMedPubMedCentral

16.

Bodei, L., Lam, M., Chiesa, C., Flux, G., Brans, B., Chiti, A., Giammarile, F.: EANM procedure guideline for treatment of refractory metastatic bone pain. Eur. J. Nucl. Med. Mol. Imaging 35(10), 1934–1940 (2008). doi:10.1007/s00259-008-0841-y CrossRefPubMed

17.

Coleman, R., Body, J.J., Aapro, M., Hadji, P., Herrstedt, J., on behalf of the, E.G.W.G: Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann. Oncol. (2014). doi:10.1093/annonc/mdu103

18.

Bradley, N.M., Husted, J., Sey, M.S., Husain, A.F., Sinclair, E., Harris, K., Chow, E.: Review of patterns of practice and patients’ preferences in the treatment of bone metastases with palliative radiotherapy. Support. Care Cancer 15(4), 373–385 (2007). doi:10.1007/s00520-006-0161-3 CrossRefPubMed

19.

Sze, W.M., Shelley, M., Held, I., Mason, M.: Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy—a systematic review of the randomised trials. Cochrane Database Syst. Rev.(2), Cd004721 (2004). doi:10.1002/14651858.cd004721

20.

Hillner, B.E., Weeks, J.C., Desch, C.E., Smith, T.J.: Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J. Clin. Oncol. 18(1), 72–79 (2000)PubMed

21.

Lage, M.J., Barber, B.L., Harrison, D.J., Jun, S.: The cost of treating skeletal-related events in patients with prostate cancer. Am. J. Manag. Care 14(5), 317–322 (2008)PubMed

22.

Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., Senkus, E., Group E.G.W: Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(Suppl 7), vii11–vii19 (2012). doi:10.1093/annonc/mds232 CrossRefPubMed

23.

Escudier, B., Eisen, T., Porta, C., Patard, J.J., Khoo, V., Algaba, F., Mulders, P., Kataja, V., Group E.G.W: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(Suppl 7), vii65–vii71 (2012). doi:10.1093/annonc/mds227 CrossRefPubMed

24.

Horwich, A., Parker, C., de Reijke, T., Kataja, V., Group E.G.W: Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl 6), vi106–vi114 (2013). doi:10.1093/annonc/mdt208 CrossRefPubMed

25.

Mottet, N., Bastian, P.J., Bellmunt, J., van den Bergh, R.C.N., Bolla, M., van Casteren, N.J., Cornford, P., Joniau, S., Mason, M.D., Matveev, V., van der Kwast, T.H., van der Poel, H., Rouvière, O., Wiegel, T.: EAU Clinical guidelines: Guidelines on Prostate Cancer. (2014). Accessed 27 May 2014

26.

Peters, S., Adjei, A.A., Gridelli, C., Reck, M., Kerr, K., Felip, E., Group E.G.W: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(Suppl 7), vii56–vii64 (2012). doi:10.1093/annonc/mds226 CrossRefPubMed

27.

Body, J.J., Diel, I.J., Lichinitser, M.R., Kreuser, E.D., Dornoff, W., Gorbunova, V.A., Budde, M., Bergstrom, B.: Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. 14(9), 1399–1405 (2003)CrossRefPubMed

28.

Theriault, R.L., Lipton, A., Hortobagyi, G.N., Leff, R., Gluck, S., Stewart, J.F., Costello, S., Kennedy, I., Simeone, J., Seaman, J.J., Knight, R.D., Mellars, K., Heffernan, M., Reitsma, D.J.: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J. Clin. Oncol. 17(3), 846–854 (1999)PubMed

29.

Saad, F., Gleason, D.M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J.L., Vinholes, J.J., Goas, J.A., Zheng, M.: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst. 96(11), 879–882 (2004)CrossRefPubMed

30.

Barrett-Lee, P., Casbard, A., Abraham, J., Hood, K., Coleman, R., Simmonds, P., Timmins, H., Wheatley, D., Grieve, R., Griffiths, G., Murray, N.: Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol. 15(1), 114–122 (2014). doi:10.1016/s1470-2045(13)70539-4 CrossRefPubMed

31.

Gordon, D.H.: Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. Clin. Breast Cancer 6(2), 125–131 (2005). doi:10.3816/CBC.2005.n.014 CrossRefPubMed

32.

Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., Jiang, Q., Tadros, S., Dansey, R., Goessl, C.: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768), 813–822 (2011). doi:10.1016/s0140-6736(10)62344-6 CrossRefPubMedPubMedCentral

33.

Henry, D., Vadhan-Raj, S., Hirsh, V., von Moos, R., Hungria, V., Costa, L., Woll, P.J., Scagliotti, G., Smith, G., Feng, A., Jun, S., Dansey, R., Yeh, H.: Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support. Care Cancer 22(3), 679–687 (2014). doi:10.1007/s00520-013-2022-1 CrossRefPubMed

34.

Lipton, A., Fizazi, K., Stopeck, A.T., Henry, D.H., Brown, J.E., Yardley, D.A., Richardson, G.E., Siena, S., Maroto, P., Clemens, M., Bilynskyy, B., Charu, V., Beuzeboc, P., Rader, M., Viniegra, M., Saad, F., Ke, C., Braun, A., Jun, S.: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur. J. Cancer 48(16), 3082–3092 (2012). doi:10.1016/j.ejca.2012.08.002 CrossRefPubMed

35.

Smith, M.R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damiao, R., Tammela, T.L., Egerdie, B., Van Poppel, H., Chin, J., Morote, J., Gomez-Veiga, F., Borkowski, T., Ye, Z., Kupic, A., Dansey, R., Goessl, C.: Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379(9810), 39–46 (2012). doi:10.1016/s0140-6736(11)61226-9 CrossRefPubMed

36.

Stopeck, A.T., Lipton, A., Body, J.J., Steger, G.G., Tonkin, K., de Boer, R.H., Lichinitser, M., Fujiwara, Y., Yardley, D.A., Viniegra, M., Fan, M., Jiang, Q., Dansey, R., Jun, S., Braun, A.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28(35), 5132–5139 (2010). doi:10.1200/jco.2010.29.7101 CrossRefPubMed

37.

Tchekmedyian, N.S., Chen, Y.M., Saad, F.: Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors. Cancer Invest. 28(8), 849–855 (2010). doi:10.3109/07357907.2010.483508 CrossRefPubMed

38.

Casas, A., Lebret, T., Cavo, M., Woll, P.J., Deleplace, C., Kennedy, C., Jackisch, C.: Insights into the management of bone metastases: a comprehensive European survey. Support. Care Cancer 20(Suppl. 1), S88 (2012)

39.

Rosen, L.S., Gordon, D.H., Dugan Jr, W., Major, P., Eisenberg, P.D., Provencher, L., Kaminski, M., Simeone, J., Seaman, J., Chen, B.L., Coleman, R.E.: Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100(1), 36–43 (2004). doi:10.1002/cncr.11892 CrossRefPubMed

40.

Smith, M.R., Coleman, R.E., Klotz, L., Pittman, K., Milecki, P., Ng, S., Chi, K.N., Balakumaran, A., Wei, R., Wang, H., Braun, A., Fizazi, K.: Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann. Oncol. 26(2), 368–374 (2015). doi:10.1093/annonc/mdu519 CrossRefPubMed

Title: Health resource utilization associated with skeletal-related events: results from a retrospective European study
Authors: Jean-Jacques Body
João Pereira
Harm Sleeboom
Nikos Maniadakis
Evangelos Terpos
Yves Pascal Acklin
Jindrich Finek
Oliver Gunther
Guy Hechmati
Tony Mossman
Luis Costa
Wojciech Rogowski
Hareth Nahi
Roger von Moos
Publication date: 01-07-2016
Publisher: Springer Berlin Heidelberg
Published in: The European Journal of Health Economics / Issue 6/2016
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-015-0716-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Health resource utilization associated with skeletal-related events: results from a retrospective European study

Abstract

Background

Objective

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2016

Economic evaluation in chronic pain: a systematic review and de novo flexible economic model

Estimating informal care inputs associated with EQ-5D for use in economic evaluation

Pay or conditions? The role of workplace characteristics in nurses’ labor supply

Health, work and working conditions: a review of the European economic literature

Burden of influenza in Germany: a retrospective claims database analysis for the influenza season 2012/2013

Predicting hospital costs for patients receiving renal replacement therapy to inform an economic evaluation